loading
Kymera Therapeutics Inc stock is traded at $30.42, with a volume of 425.50K. It is down -2.91% in the last 24 hours and down -20.92% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$31.35
Open:
$31.66
24h Volume:
425.50K
Relative Volume:
0.83
Market Cap:
$1.98B
Revenue:
$87.56M
Net Income/Loss:
$-167.47M
P/E Ratio:
-13.00
EPS:
-2.34
Net Cash Flow:
$-148.20M
1W Performance:
-13.80%
1M Performance:
-20.92%
6M Performance:
-34.29%
1Y Performance:
-30.03%
1-Day Range:
Value
$29.90
$31.66
1-Week Range:
Value
$29.16
$36.36
52-Week Range:
Value
$29.16
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
Name
Kymera Therapeutics Inc
Name
Phone
857-285-5314
Name
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
Employee
188
Name
Twitter
Name
Next Earnings Date
2025-02-21
Name
Latest SEC Filings
Name
KYMR's Discussions on Twitter

Compare KYMR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
30.50 1.98B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.92 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
688.49 75.07B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
634.75 37.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.37 31.79B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
112.68 27.34B 3.30B -501.07M 1.03B -2.1146

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-10-24 Initiated BTIG Research Buy
Dec-06-24 Initiated BMO Capital Markets Market Perform
Dec-02-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-18-24 Initiated Stephens Overweight
Sep-09-24 Resumed Leerink Partners Outperform
Aug-26-24 Upgrade Wolfe Research Peer Perform → Outperform
Apr-22-24 Initiated Oppenheimer Outperform
Feb-15-24 Initiated Wolfe Research Peer Perform
Jan-04-24 Upgrade JP Morgan Neutral → Overweight
Jan-03-24 Downgrade BofA Securities Buy → Neutral
Dec-19-23 Downgrade Wells Fargo Overweight → Equal Weight
Jun-30-23 Initiated Truist Buy
May-05-23 Upgrade Raymond James Mkt Perform → Outperform
Dec-06-22 Downgrade Credit Suisse Outperform → Neutral
Nov-08-22 Initiated Raymond James Mkt Perform
Aug-15-22 Initiated Jefferies Buy
Aug-03-22 Initiated Goldman Buy
Jul-20-22 Initiated SVB Leerink Mkt Perform
Apr-28-22 Initiated Credit Suisse Outperform
Mar-10-22 Initiated JP Morgan Neutral
Feb-10-22 Initiated Wells Fargo Overweight
Sep-30-21 Initiated B. Riley Securities Neutral
Sep-30-21 Initiated Stifel Buy
Sep-10-21 Downgrade BofA Securities Buy → Neutral
May-21-21 Initiated UBS Buy
Apr-14-21 Initiated Berenberg Buy
Dec-04-20 Initiated H.C. Wainwright Buy
Sep-15-20 Initiated BofA Securities Neutral
Sep-15-20 Initiated Cowen Outperform
Sep-15-20 Initiated Guggenheim Buy
Sep-15-20 Initiated Morgan Stanley Equal-Weight
View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

pulisher
03:50 AM

Q3 Earnings Forecast for KYMR Issued By HC Wainwright - Defense World

03:50 AM
pulisher
02:29 AM

Analysts Set Expectations for KYMR Q2 Earnings - Defense World

02:29 AM
pulisher
01:55 AM

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 - Defense World

01:55 AM
pulisher
Mar 01, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Mar 01, 2025
pulisher
Mar 01, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance

Mar 01, 2025
pulisher
Mar 01, 2025

Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

(KYMR) Trading Signals - Stock Traders Daily

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics Inc (KYMR) Volatility Hits 9.22%: What Good Investors Need To Be Aware Of - Stocks Register

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics stock target cut to $54 by H.C. Wainwright - Investing.com Canada

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus.com

Feb 28, 2025
pulisher
Feb 28, 2025

Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

Kymera Therapeutics (NASDAQ:KYMR) Reaches New 52-Week Low After Earnings Miss - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera stock hits 52-week low at $29.23 amid market challenges - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera stock hits 52-week low at $29.23 amid market challenges By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics misses Q4 estimates, shares dip By Investing.com - Investing.com Australia

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics misses Q4 estimates, shares dip - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls -February 27, 2025 at 08:54 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

KYMERA THERAPEUTICS Earnings Results: $KYMR Reports Quarterly Earnings - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Revenue $7.4M, vs. FactSet Est of $14.4M - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Can Kymera's $851M War Chest Deliver on Its Promising Immunology Pipeline Despite Widening Losses? - StockTitan

Feb 27, 2025
pulisher
Feb 26, 2025

What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings - Yahoo Finance

Feb 26, 2025
pulisher
Feb 26, 2025

Kymera Therapeutics to Participate in Upcoming March Investor Conferences - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Kymera Therapeutics Sets Investor Conference Calendar: Four Key Healthcare Events Where You'll Hear Their Story - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Head to Head Analysis: Kymera Therapeutics (NASDAQ:KYMR) and Creative Medical Technology (NASDAQ:CELZ) - Defense World

Feb 25, 2025
pulisher
Feb 23, 2025

Assured Guaranty, Kymera rise; BP, Helen of Troy fall, Tuesday, 7/9/2024 - MSN

Feb 23, 2025
pulisher
Feb 23, 2025

Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Feb 23, 2025
pulisher
Feb 21, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 21, 2025
pulisher
Feb 20, 2025

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance - MSN

Feb 20, 2025
pulisher
Feb 20, 2025

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Kymera Therapeutics (KYMR) Expected to Announce Earnings on Thursday - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR) - Seeking Alpha

Feb 19, 2025
pulisher
Feb 18, 2025

When the Price of (KYMR) Talks, People Listen - Stock Traders Daily

Feb 18, 2025
pulisher
Feb 17, 2025

Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely - Simply Wall St

Feb 17, 2025
pulisher
Feb 17, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Feb 17, 2025
pulisher
Feb 14, 2025

Kymera rises after presentation at the J.P. Morgan event - MSN

Feb 14, 2025
pulisher
Feb 09, 2025

SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Jennison Associates LLC Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM) - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Financial Snapshot: Analyzing Kymera Therapeutics Inc (KYMR)’s Key Ratio Metrics - The Dwinnex

Feb 07, 2025

Kymera Therapeutics Inc Stock (KYMR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.49
price down icon 3.91%
$23.04
price up icon 1.68%
$33.97
price up icon 1.09%
$19.98
price down icon 3.21%
biotechnology ONC
$244.72
price down icon 9.96%
$112.79
price down icon 0.24%
Cap:     |  Volume (24h):